CO6190532A2 - Inhibidores heteroaril biciclicos de pde4, metodos para su sintesis y metodos para inhibir pde4 - Google Patents

Inhibidores heteroaril biciclicos de pde4, metodos para su sintesis y metodos para inhibir pde4

Info

Publication number
CO6190532A2
CO6190532A2 CO09010461A CO09010461A CO6190532A2 CO 6190532 A2 CO6190532 A2 CO 6190532A2 CO 09010461 A CO09010461 A CO 09010461A CO 09010461 A CO09010461 A CO 09010461A CO 6190532 A2 CO6190532 A2 CO 6190532A2
Authority
CO
Colombia
Prior art keywords
group
amino
pde4
alkoxy
methods
Prior art date
Application number
CO09010461A
Other languages
English (en)
Inventor
Steven Govek
Andrew Shiau
Stewart Noble
David J Thomas
Original Assignee
Steven Govek
Andrew Shiau
Stewart Noble
David J Thomas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steven Govek, Andrew Shiau, Stewart Noble, David J Thomas filed Critical Steven Govek
Publication of CO6190532A2 publication Critical patent/CO6190532A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

1.- Un método de inhibición de PDE4 que comprende poner en contacto PDE4 con un compuesto de Fórmula estructural IVo una de sus sales, ésteres o profármacos, en donde: X3 es (CR18 R19); R1 y R2 se seleccionan de modo independiente del grupo que consiste en -(CH2)sG1G2G3, acilo, acilalquilo, carboxialquilo, cianoalquilo, alcoxi, alcoxialquilo, amidoalquilo, amino, alquilo, alquilalcoxi, aminoalquilo, alquenilo, alquinilo, carboxilo, carboxialquilo, éter, heteroalquilo, haloalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, aralquilo, arilo, guanidina, heteroarilo, heteroaralquilo, hidrógeno y hidroxialquilo, alguno de los cuales puede estar opcionalmente sustituido; s es 1-8; G1 se selecciona del grupo que consiste en alcoxi, amino, amido, carbonilo, hidroxi, éter, un aminoácido, y nulo; G2 se selecciona del grupo que consiste en alquilo, alcoxi, amino, arilo, halo, haloalquilo, heterocicloalquilo, heteroarilo, carboxilalquilamino, guanidina, un aminoácido, y nulo, alguno de los cuales puede estar opcionalmente sustituido;G3 se selecciona del grupo que consiste en alquilo, alcoxi, amino, hidroxi, éter, carboxilo, ácido hidroxámico, un aminoácido, fosfonato, fosfoamida, y nulo, alguno de los cuales puede estar opcionalmente sustituido; R3 y R4 se seleccionan de modo independiente del grupo que consiste en hidrógeno, halógeno, alcoxi y alquilo inferior;R5 se selecciona del grupo que consiste en (CR8R9)mW(CR10R11)n- y -(CR12R13)p-; W se selecciona del grupo que consiste en O, N(R7), C(O)N(R7), y SOq; m, n, y q son de modo independiente 0, 1 o 2; p es 1 o 2; R6 se selecciona del grupo que consiste en carboxilo, alquilcarboxi, amido, arilo, heteroarilo, cicloalquilo, ...
CO09010461A 2006-07-07 2009-02-04 Inhibidores heteroaril biciclicos de pde4, metodos para su sintesis y metodos para inhibir pde4 CO6190532A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81950906P 2006-07-07 2006-07-07
US88682507P 2007-01-26 2007-01-26

Publications (1)

Publication Number Publication Date
CO6190532A2 true CO6190532A2 (es) 2010-08-19

Family

ID=38739981

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09010461A CO6190532A2 (es) 2006-07-07 2009-02-04 Inhibidores heteroaril biciclicos de pde4, metodos para su sintesis y metodos para inhibir pde4

Country Status (11)

Country Link
US (5) US20090291950A1 (es)
EP (1) EP2037924A2 (es)
JP (2) JP5280357B2 (es)
KR (2) KR20150004441A (es)
CN (1) CN104606194A (es)
AU (1) AU2007269070B2 (es)
BR (1) BRPI0713253A2 (es)
CA (1) CA2657093A1 (es)
CO (1) CO6190532A2 (es)
MX (1) MX2009000148A (es)
WO (3) WO2008006052A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DK1861074T3 (da) * 2005-03-16 2013-07-29 Takeda Gmbh Smagsmaskeret doseringsform indeholdende roflumilast
US8138205B2 (en) * 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
KR20150004441A (ko) 2006-07-07 2015-01-12 칼립시스, 인코포레이티드 Ｐｄｅ４의 바이사이클릭 헤테로아릴 억제제
US9486441B2 (en) 2008-04-21 2016-11-08 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
CN101353338B (zh) * 2008-07-10 2011-05-04 上海交通大学 糖胺改性的水溶性香豆素酮衍生物及其制备方法
AU2010300421B2 (en) * 2009-10-01 2014-01-23 Alcon Research, Ltd. Olopatadine compositions and uses thereof
JP5807058B2 (ja) 2010-05-10 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド 二機能キノリン誘導体
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
US20130116279A1 (en) * 2011-11-07 2013-05-09 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CA2900302C (en) 2013-02-19 2018-07-03 Pfizer Inc. Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP2958895B1 (en) 2013-02-20 2020-08-19 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN106061261B (zh) 2013-11-01 2018-04-24 卡拉制药公司 治疗化合物的结晶形式及其用途
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
BR112018012949B1 (pt) 2015-12-24 2023-11-14 The Regents Of The University Of California Reguladores cftr e métodos de uso dos mesmos
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
CN106916104B (zh) * 2017-02-28 2019-08-27 牡丹江医学院 用于治疗结肠炎的药物
JP7217259B2 (ja) * 2017-07-26 2023-02-02 エイチジーアンドエイチ ファーマスーティカルズ（ピーティワイ）リミテッド てんかん及び関連疾患を患う患者の予防及び治療のためのメセンブレノール及び／又はメセンブラノール
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions
JP2022518292A (ja) * 2019-01-23 2022-03-14 パス セラピューティクス，インク． ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法
US20220371990A1 (en) * 2019-09-08 2022-11-24 Hadasit Medical Research Services And Developmect Ltd. Anti-fibrotic compounds and use thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US542104A (en) * 1895-07-02 Nut-sheller
AU639529B2 (en) 1987-03-04 1993-07-29 Higuchi, Yoshinari Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
EP0396620B1 (en) * 1988-01-15 1993-08-11 Abbott Laboratories Aminomethyl-chroman and -thiochroman compounds
DE69128481T2 (de) 1990-09-07 1998-04-09 Schering Corp Antivirale und antihypertensive verbindungen
EP0533882B1 (en) 1991-04-03 2001-02-07 Korea Research Institute Of Chemical Technology 2-quinolinone derivatives, methods for preparing the same and fungicides and insecticides including them
EP0670833A1 (de) 1992-11-27 1995-09-13 Iovis Biomedical And Pharmaceutical Consultants Nitroxyverbindungen mit pharmazeutischen eigenschaften
FR2703683B1 (fr) 1993-04-08 1995-07-07 Seractec Dérivés d'aminocoumarines hydrophobes, et leur utilisation comme substrats d'enzymes protéolytiques ou pour la préparation de tels substrats.
FR2711992A1 (fr) 1993-11-03 1995-05-12 Lipha Nouveaux dérivé hétérocycliques, procédé de préparation et composition pharmaceutique les contenant.
DE4337906A1 (de) 1993-11-08 1995-05-11 Cassella Ag Verwendung von Cumarinderivaten
US5563280A (en) 1994-07-25 1996-10-08 American Cyanamid Co. 4-Phenoxycoumarins as herbicidal agents
JP2000500739A (ja) 1995-10-13 2000-01-25 アグレボ・ユー・ケイ・リミテツド 複素環式殺菌剤
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
US20040081959A9 (en) 1999-12-08 2004-04-29 Epoch Biosciences, Inc. Fluorescent quenching detection reagents and methods
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
US6436971B2 (en) * 2000-02-09 2002-08-20 Smithkline Beecham Corporation Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection
DE10021256A1 (de) * 2000-04-20 2001-10-31 Forschungsverbund Berlin Ev Neue, photolabile Cumarinylmethylester von cyclischen Nucleotiden, Verfahren zu deren Herstellung und ihre Verwendung
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
AP1666A (en) 2000-09-11 2006-09-29 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors.
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
JP2002371078A (ja) 2001-06-12 2002-12-26 Sankyo Co Ltd キノリン誘導体及びキノロン誘導体
JP2003146972A (ja) * 2001-11-14 2003-05-21 Teikoku Hormone Mfg Co Ltd カルボスチリル誘導体
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US7148253B2 (en) 2002-05-14 2006-12-12 Xtl Biopharmaceuticals Ltd. 4-thio coumarins
EP1504000A4 (en) 2002-05-14 2006-08-23 Vivoquest Inc 4-THIOCOUMARINE
WO2004011446A1 (en) * 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
WO2004018419A2 (en) 2002-08-23 2004-03-04 Chiron Corporation Benzimidazole quinolinones and uses thereof
CN1506359A (zh) 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
ITMI20022739A1 (it) * 2002-12-23 2004-06-24 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4.
JP2007505835A (ja) 2003-09-15 2007-03-15 シグナル ファーマシューティカルズ，エルエルシー ベンゾピラノン化合物、その組成物及びそれを用いた治療方法
EP1718306A2 (en) 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
CA2565599C (en) * 2004-05-18 2012-07-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
AP2446A (en) 2004-09-22 2012-08-31 Janssen Pharmaceutica Nv Inhibitors of the interaction between MDM2 and P53
WO2006083692A2 (en) * 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
NL1028569C2 (nl) 2005-03-18 2006-09-20 Rademaker Holding B V Toepassing van een coumarine-groep omvattende derivaten voor de bereiding van een antiviraal middel, alsmede kattenvoer.
US8048889B2 (en) 2005-03-29 2011-11-01 Xtl Biopharmaceuticals Ltd. 3,4-disubstituted coumarin and quinolone compounds
BRPI0616452B8 (pt) 2005-09-30 2021-05-25 Argenta Discovery Ltd quinolinas e seu uso terapêutico
US8138205B2 (en) * 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
KR20150004441A (ko) 2006-07-07 2015-01-12 칼립시스, 인코포레이티드 Ｐｄｅ４의 바이사이클릭 헤테로아릴 억제제
US20130116279A1 (en) * 2011-11-07 2013-05-09 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4

Also Published As

Publication number Publication date
KR20150004441A (ko) 2015-01-12
WO2008006051A3 (en) 2008-06-26
WO2008006051A2 (en) 2008-01-10
US20080027112A1 (en) 2008-01-31
WO2008006050A2 (en) 2008-01-10
US20080027099A1 (en) 2008-01-31
MX2009000148A (es) 2009-10-26
WO2008006052A3 (en) 2008-11-20
JP2013177421A (ja) 2013-09-09
KR20090109527A (ko) 2009-10-20
WO2008006052A2 (en) 2008-01-10
CA2657093A1 (en) 2008-01-10
BRPI0713253A2 (pt) 2012-10-30
WO2008006050A3 (en) 2008-06-26
US20090291950A1 (en) 2009-11-26
EP2037924A2 (en) 2009-03-25
US8080563B2 (en) 2011-12-20
CN104606194A (zh) 2015-05-13
JP5705269B2 (ja) 2015-04-22
US20130178498A1 (en) 2013-07-11
AU2007269070A1 (en) 2008-01-10
US9078887B2 (en) 2015-07-14
JP2009542815A (ja) 2009-12-03
JP5280357B2 (ja) 2013-09-04
US7745646B2 (en) 2010-06-29
US8258154B2 (en) 2012-09-04
US20100022586A1 (en) 2010-01-28
AU2007269070B2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
CO6190532A2 (es) Inhibidores heteroaril biciclicos de pde4, metodos para su sintesis y metodos para inhibir pde4
ATE530614T1 (de) Neues hydrogelbildendes mittel auf lipid- tripeptid-basis und hydrogel
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
TN2009000012A1 (en) Amino-piperidine derivatives as cetp inhibitors
EA200970172A1 (ru) Пролекарство соединения амида коричной кислоты
UA102336C2 (uk) N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ
EA201000884A1 (ru) Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
WO2008114819A1 (ja) 新規アデニン化合物
ECSP055883A (es) Nuevos derivados de piridazin-3(2h)-ona
EA200500862A1 (ru) Синоменин и соединения синоменина, синтез и применение
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
TW200642683A (en) Heterocyclic compound
ES2571483T3 (es) Producto intermedio para producir un éster de ácido sulfónico cíclico
MX2008014898A (es) Composicion para el diagnostico de enfermedades relacionadas con amiloides.
NO20082630L (no) Vann-opploslige benzoazepinforbindelser og farmasoytisk forbindelse
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
EA200700360A1 (ru) Новые производные амида гетероциклической карбоновой кислоты
ATE466838T1 (de) Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer
EA201001087A1 (ru) Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их
MX2011011281A (es) Compuesto de carbinol que tiene un enlazante heterociclico.
GB2570549A8 (en) Acid gas absorbent, acid gas removal method, and acid gas removal device
CR8340A (es) Pirazolilcarboxanilidas n-sustituidas
MX2010006446A (es) Nuevos derivados de diazeniodiolato, procedimiento para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
EA200501530A1 (ru) Новые соединения бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FG Application granted